Biomarin Pharmaceutical price to free cash flow BMRN

Market value divided by free cash flow over the last twelve months, since 2021.

Today, Oct 23, 2026: 14.7×
5-year median: 79.1×
Against its 5-year history: 13th; percentile: 0 is its lowest day, 100 its highest
5-year range: 11.9× to 499×
Peer median: 50.9×

Biomarin Pharmaceutical's price to free cash flow is 14.7× as of Oct 23, 2026.

That is below its 5-year median of 79.1×, lower than on 87% of days in the last 5 years.

Over that time it ranged from 11.9× in Nov 2025 to 499× in Dec 2023.

The median for 10 large drugmakers of a similar size is 50.9×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	14.7×	12.6×	17.7×
2025	13.8×	11.9×	40.7×
2024	39.9×	37.8×	495×
2023	499×	286×	499×
2022	290×	66.9×	353×
2021	89.1×	78.0×	136×

Against its peers

Companies in Drug Manufacturers - General nearest Biomarin Pharmaceutical's size, closest first, today.

Company	Price to free cash flow
BMRNBiomarin Pharmaceutical	14.7×
CORTCorcept Therapeutics	86.8×
PTGXProtagonist Therapeutics	68.6×
JAZZJazz Pharmaceuticals	8.7×
TGTXTG Therapeutics	477×
ALKSAlkermes plc.	33.0×
AMRXAmneal Pharmaceuticals	50.9×
LGNDLigand Pharmaceuticals	46.0×
KNSAKiniksa Pharmaceuticals International	32.7×
INDVIndivior Pharmaceuticals	n/m
ARQTArcutis Biotherapeutics	100×
Peer median	50.9×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Biomarin Pharmaceutical

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.